ATE177095T1 - Substituierte piperidine für die behandlung von allergischen krankheiten - Google Patents

Substituierte piperidine für die behandlung von allergischen krankheiten

Info

Publication number: ATE177095T1
Authority: AT; Austria
Prior art keywords: treatment; substituted piperidine; allergic diseases; useful; antagonists
Prior art date: 1994-08-25

Application number

AT95931551T

Other languages

English (en)

Inventor

Timothy P Burkholder

Larry D Bratton

Elizabeth M Kudlacz

George D Maynard

John M Kane

Braulio Santiago

Original Assignee

Merrell Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-08-25

Filing date

1995-08-17

Publication date

1999-03-15

1995-08-17 Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc

1999-03-15 Application granted granted Critical

1999-03-15 Publication of ATE177095T1 publication Critical patent/ATE177095T1/de

Links

NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
230000000172 allergic effect Effects 0.000 title 1
208000010668 atopic eczema Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
208000036284 Rhinitis seasonal Diseases 0.000 abstract 2
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 abstract 1
206010049153 Allergic sinusitis Diseases 0.000 abstract 1
229940122236 Histamine receptor antagonist Drugs 0.000 abstract 1
208000026935 allergic disease Diseases 0.000 abstract 1
201000010105 allergic rhinitis Diseases 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
150000003053 piperidines Chemical class 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
208000017022 seasonal allergic rhinitis Diseases 0.000 abstract 1
239000002462 tachykinin receptor antagonist Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)

AT95931551T 1994-08-25 1995-08-17 Substituierte piperidine für die behandlung von allergischen krankheiten ATE177095T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29596094A	1994-08-25	1994-08-25
US50191495A	1995-07-13	1995-07-13

Publications (1)

Publication Number	Publication Date
ATE177095T1 true ATE177095T1 (de)	1999-03-15

Family

ID=26969426

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95931551T ATE177095T1 (de)	1994-08-25	1995-08-17	Substituierte piperidine für die behandlung von allergischen krankheiten

Country Status (20)

Country	Link
US (1)	US6329392B1 (de)
EP (1)	EP0777666B1 (de)
JP (1)	JPH10504580A (de)
KR (1)	KR100362620B1 (de)
CN (1)	CN1067385C (de)
AT (1)	ATE177095T1 (de)
AU (1)	AU693936B2 (de)
CA (1)	CA2198084C (de)
DE (1)	DE69508093T2 (de)
DK (1)	DK0777666T3 (de)
ES (1)	ES2132709T3 (de)
FI (1)	FI114470B (de)
GR (1)	GR3030253T3 (de)
HU (1)	HU221434B (de)
IL (1)	IL115040A (de)
MX (1)	MX9701305A (de)
NO (1)	NO313237B1 (de)
NZ (1)	NZ292683A (de)
TW (1)	TW430663B (de)
WO (1)	WO1996006094A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH11513991A (ja) *	1995-11-17	1999-11-30	ヘキスト・マリオン・ルセル・インコーポレイテツド	アレルギー性疾患の治療に有用な置換４−（１ｈ−ベンズイミダゾル−２−イル−アミノ）ピペリジン
US6211199B1 (en)	1995-11-17	2001-04-03	Aventis Pharmaceuticals Inc.	Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
US6194406B1 (en)	1995-12-20	2001-02-27	Aventis Pharmaceuticals Inc.	Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
IL125002A0 (en) *	1995-12-20	1999-01-26	Hoechst Marion Roussel Inc	Novel substituted 4-(1H-benzimidazol-2-yl) [1,4] diazepanes useful for the treatment of allergic diseases
US6423704B2 (en)	1995-12-20	2002-07-23	Aventis Pharmaceuticals Inc.	Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
US5932571A (en) *	1996-02-21	1999-08-03	Hoechst Marion Roussel, Inc.	Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US5998439A (en) *	1996-02-21	1999-12-07	Hoescht Marion Roussel, Inc.	Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
CN1115341C (zh) *	1996-02-21	2003-07-23	阿温蒂斯药物公司	用于治疗过敏性疾病的新的取代的n－甲基－n－(4－(4－(1h－苯并咪唑－2－基氨基)哌啶－1－基)－2－(芳基)丁基)苯甲酰胺
CN1143856C (zh) *	1996-02-21	2004-03-31	阿温蒂斯药物公司	可用于治疗过敏性疾病的新的取代的 n－甲基－ n － ( 4 － ( 4 － ( 1 h－苯并咪唑－ 2 －基 ) [ 1 , 4 ]二氮杂环庚烷－1－基)－2－(芳基)丁基)苯甲酰胺类化合物
FR2755133B1 (fr) *	1996-10-31	1999-01-15	Sanofi Sa	Nouveaux derives d'amides cycliques diversement substitues antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
FR2759585B1 (fr)	1997-02-17	1999-06-11	Sanofi Sa	Formulations pharmaceutiques presentees sous forme seche pour l'administration orale d'un compose ammonium quaternaire cyclique
FR2759584B1 (fr) *	1997-02-17	1999-06-11	Sanofi Sa	Composition pharmaceutique pour l'administration orale de composes heterocycliques sous forme ammonium quaternaire
GB9821898D0 (en) *	1998-10-08	1998-12-02	Pfizer Ltd	Heterocycles
JP2002527381A (ja) *	1998-10-09	2002-08-27	シェーリングコーポレイション	アレルギー性疾患を処置するための組成物および方法
US6103735A (en) *	1998-10-09	2000-08-15	Schering Corporation	Composition and method for treating allergic diseases
FR2789390B3 (fr) *	1999-02-10	2001-03-09	Sanofi Sa	Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
US7163949B1 (en)	1999-11-03	2007-01-16	Amr Technology, Inc.	4-phenyl substituted tetrahydroisoquinolines and use thereof
WO2001032625A1 (en)	1999-11-03	2001-05-10	Du Pont Pharmaceuticals Company	Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
AU784813B2 (en) *	2000-01-17	2006-06-29	Bayer Aktiengesellschaft	Substituted aryl ketones
JP5132864B2 (ja)	2000-07-11	2013-01-30	アルバニーモレキュラーリサーチ，インコーポレイテッド	４−フェニル置換テトラヒドロイソキノリンおよびその使用方法
WO2002079146A2 (en) *	2001-03-02	2002-10-10	Bristol-Myers Squibb Company	Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
SE0302116D0 (sv) *	2003-07-21	2003-07-21	Astrazeneca Ab	Novel compounds
GB0326407D0 (en) *	2003-11-12	2003-12-17	Glaxo Group Ltd	Chemical compounds
AU2005274927B2 (en)	2004-07-15	2011-11-03	Albany Molecular Research, Inc.	Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8362075B2 (en)	2005-05-17	2013-01-29	Merck Sharp & Dohme Corp.	Cyclohexyl sulphones for treatment of cancer
KR101594898B1 (ko)	2005-07-15	2016-02-18	알바니 몰레큘라 리써치, 인크.	아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
KR20080048502A (ko)	2005-09-29	2008-06-02	머크 앤드 캄파니 인코포레이티드	멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
GB0603041D0 (en)	2006-02-15	2006-03-29	Angeletti P Ist Richerche Bio	Therapeutic compounds
US8173629B2 (en)	2006-09-22	2012-05-08	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EA016079B1 (ru)	2007-01-10	2012-01-30	Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа	Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
JP2010516731A (ja)	2007-01-24	2010-05-20	グラクソグループリミテッド	２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
JP5319518B2 (ja)	2007-04-02	2013-10-16	Ｍｓｄ株式会社	インドールジオン誘導体
AU2008269154B2 (en)	2007-06-27	2014-06-12	Merck Sharp & Dohme Llc	4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN102014631A (zh)	2008-03-03	2011-04-13	泰格尔医药科技公司	酪氨酸激酶抑制剂
US9156812B2 (en)	2008-06-04	2015-10-13	Bristol-Myers Squibb Company	Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en)	2009-04-01	2010-10-07	Merck Sharp & Dohme Corp.	Inhibitors of akt activity
US7918821B2 (en)	2009-05-05	2011-04-05	Mahurkar Sakharam D	Universal safety syringe
US8802696B2 (en)	2009-05-12	2014-08-12	Albany Molecular Research, Inc.	7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
WO2010132487A1 (en)	2009-05-12	2010-11-18	Bristol-Myers Squibb Company	CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
CN102458123A (zh)	2009-05-12	2012-05-16	阿尔巴尼分子研究公司	芳基、杂芳基和杂环取代的四氢异喹啉及其用途
WO2011026241A1 (en) *	2009-09-04	2011-03-10	Zalicus Pharmaceuticals Ltd.	Substituted heterocyclic derivatives for the treatment of pain and epilepsy
JP5099731B1 (ja)	2009-10-14	2012-12-19	メルク・シャープ・アンド・ドーム・コーポレーション	ｐ５３活性を増大する置換ピペリジン及びその使用
EP2584903B1 (de)	2010-06-24	2018-10-24	Merck Sharp & Dohme Corp.	Neue heterozyklische verbindungen als erk-hemmer
AU2011285909B2 (en)	2010-08-02	2016-11-10	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (de)	2010-08-17	2019-04-10	Sirna Therapeutics, Inc.	Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina)
US8883801B2 (en)	2010-08-23	2014-11-11	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (de)	2010-09-01	2016-11-02	Merck Sharp & Dohme Corp.	Indazolderivate als erk-hemmer
US9242981B2 (en)	2010-09-16	2016-01-26	Merck Sharp & Dohme Corp.	Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (de)	2010-10-29	2021-01-20	Sirna Therapeutics, Inc.	Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
EP2654748B1 (de)	2010-12-21	2016-07-27	Merck Sharp & Dohme Corp.	Indazolderivate als erk-hemmer
EP2699567A1 (de)	2011-04-21	2014-02-26	Merck Sharp & Dohme Corp.	Hemmer des insulinähnlichen wachstumsfaktor-1-rezeptors
WO2013063214A1 (en)	2011-10-27	2013-05-02	Merck Sharp & Dohme Corp.	Novel compounds that are erk inhibitors
EP3358013B1 (de)	2012-05-02	2020-06-24	Sirna Therapeutics, Inc.	Sina-zusammensetzungen
KR20150060724A (ko)	2012-09-28	2015-06-03	머크 샤프 앤드 돔 코포레이션	Erk 억제제인 신규 화합물
DK2925888T3 (en)	2012-11-28	2017-12-18	Merck Sharp & Dohme	COMPOSITIONS AND METHODS OF CANCER TREATMENT
EP2935263B1 (de)	2012-12-20	2018-12-05	Merck Sharp & Dohme Corp.	Substituierte imidazopyridine als hdm2 inhibitoren
US9540377B2 (en)	2013-01-30	2017-01-10	Merck Sharp & Dohme Corp.	2,6,7,8 substituted purines as HDM2 inhibitors
WO2014134306A1 (en)	2013-03-01	2014-09-04	Zalicus Pharmaceuticals, Ltd.	Heterocyclic inhibitors of the sodium channel
WO2015034925A1 (en)	2013-09-03	2015-03-12	Moderna Therapeutics, Inc.	Circular polynucleotides
US11589583B2 (en) *	2013-12-03	2023-02-28	Fmc Corporation	Pyrrolidinones herbicides
WO2018071283A1 (en)	2016-10-12	2018-04-19	Merck Sharp & Dohme Corp.	Kdm5 inhibitors
CN110662541B (zh) *	2017-03-12	2023-02-10	王晓冬	多环胺作为阿片受体调节剂
US11098059B2 (en)	2017-11-08	2021-08-24	Merck Sharp & Dohme Corp.	PRMT5 inhibitors
WO2019094311A1 (en)	2017-11-08	2019-05-16	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
EP3833667B1 (de)	2018-08-07	2024-03-13	Merck Sharp & Dohme LLC	Prmt5-inhibitoren
EP3833668B1 (de)	2018-08-07	2025-03-19	Merck Sharp & Dohme LLC	Prmt5-inhibitoren
BR112021002267A8 (pt)	2018-08-07	2023-02-07	Merck Sharp & Dohme	Inibidores de prmt5

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR517589A (fr)	1920-06-22	1921-05-07	Simon Et Muller	Soc de charrue
US3282947A (en)	1962-05-17	1966-11-01	Geschickter Fund Med Res	Unsymmetrically substituted 3, 9-diazaspiro(5, 5)undecane compounds
BE794598A (fr)	1972-01-28	1973-05-16	Richardson Merrell Inc	Nouveaux derives olefiniques de piperidines substituees en 4 et leur procede de preparation
JPS6157311B2 (de)	1975-01-16	1986-12-06	Robins Co Inc A H
US4254130A (en)	1979-04-10	1981-03-03	Richardson-Merrell Inc.	Piperidine derivatives
US4254129A (en)	1979-04-10	1981-03-03	Richardson-Merrell Inc.	Piperidine derivatives
US4285958A (en)	1979-04-10	1981-08-25	Richardson-Merrell Inc.	1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof
JPS5790018A (en)	1980-11-27	1982-06-04	Toray Ind Inc	Stabilized polyphenylene sulfide and its production
DE3132882A1 (de)	1981-08-20	1983-03-03	Cassella Ag, 6000 Frankfurt	Neue piperazinone, ihre herstellung und verwendung
US4666905A (en)	1983-06-02	1987-05-19	Warner-Lambert Company	Diphenylmethylene piperidines compositions and methods for their use
GB8321157D0 (en)	1983-08-05	1983-09-07	Fordonal Sa	Piperidine derivatives
EP0360390A1 (de)	1988-07-25	1990-03-28	Glaxo Group Limited	Spirolactamderivate
US4908372A (en)	1988-10-13	1990-03-13	Merrell Dow Pharmaceuticals Inc.	Antihistaminic piperidinyl benzimidazoles
IE903957A1 (en)	1989-11-06	1991-05-08	Sanofi Sa	Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
IL99320A (en)	1990-09-05	1995-07-31	Sanofi Sa	Arylalkylamines, their preparation and pharmaceutical compositions containing them
WO1992006086A1 (en)	1990-10-01	1992-04-16	Janssen Pharmaceutica N.V.	Novel 4-piperidinylcarbonyl derivatives
GB9023116D0 (en)	1990-10-24	1990-12-05	Fujisawa Pharmaceutical Co	Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
FR2676053B1 (fr)	1991-05-03	1993-08-27	Sanofi Elf	Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2676055B1 (fr) *	1991-05-03	1993-09-03	Sanofi Elf	Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
GB9113219D0 (en)	1991-06-19	1991-08-07	Fujisawa Pharmaceutical Co	Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same
TW202432B (de)	1991-06-21	1993-03-21	Pfizer
AU2031692A (en)	1991-07-22	1993-01-28	Zyma S.A.	Arylalkylamine derivatives
GB9200535D0 (en)	1992-01-10	1992-02-26	Fujisawa Pharmaceutical Co	New compound
FR2688219B1 (fr)	1992-03-03	1994-07-08	Sanofi Elf	Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
ES2048109B1 (es)	1992-07-20	1994-12-16	Espanola Prod Quimicos	Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol.
HU224496B1 (hu)	1993-05-06	2005-10-28	Merrel Dow Pharmaceuticals Inc.	Pirrolidin-3-il-alkil-piperidin-származékok és e vegyületeket tartalmazó gyógyászati készítmények

1995
- 1995-08-17 DK DK95931551T patent/DK0777666T3/da active
- 1995-08-17 AU AU34928/95A patent/AU693936B2/en not_active Ceased
- 1995-08-17 CN CN95195283A patent/CN1067385C/zh not_active Expired - Fee Related
- 1995-08-17 WO PCT/US1995/010640 patent/WO1996006094A1/en not_active Ceased
- 1995-08-17 KR KR1019970701189A patent/KR100362620B1/ko not_active Expired - Fee Related
- 1995-08-17 ES ES95931551T patent/ES2132709T3/es not_active Expired - Lifetime
- 1995-08-17 MX MX9701305A patent/MX9701305A/es unknown
- 1995-08-17 EP EP95931551A patent/EP0777666B1/de not_active Expired - Lifetime
- 1995-08-17 HU HU9701257A patent/HU221434B/hu not_active IP Right Cessation
- 1995-08-17 NZ NZ292683A patent/NZ292683A/en unknown
- 1995-08-17 DE DE69508093T patent/DE69508093T2/de not_active Expired - Fee Related
- 1995-08-17 JP JP8508257A patent/JPH10504580A/ja not_active Ceased
- 1995-08-17 CA CA002198084A patent/CA2198084C/en not_active Expired - Fee Related
- 1995-08-17 AT AT95931551T patent/ATE177095T1/de not_active IP Right Cessation
- 1995-08-23 TW TW084108797A patent/TW430663B/zh not_active IP Right Cessation
- 1995-08-23 IL IL11504095A patent/IL115040A/xx not_active IP Right Cessation
1997
- 1997-02-24 FI FI970771A patent/FI114470B/fi not_active IP Right Cessation
- 1997-02-24 NO NO19970831A patent/NO313237B1/no unknown
1998
- 1998-05-15 US US09/079,924 patent/US6329392B1/en not_active Expired - Fee Related
1999
- 1999-05-19 GR GR990401346T patent/GR3030253T3/el unknown

Also Published As

Publication number	Publication date
KR970705556A (ko)	1997-10-09
CN1067385C (zh)	2001-06-20
CN1158612A (zh)	1997-09-03
FI970771A0 (fi)	1997-02-24
FI114470B (fi)	2004-10-29
IL115040A0 (en)	1995-12-08
CA2198084A1 (en)	1996-02-29
EP0777666A1 (de)	1997-06-11
WO1996006094A1 (en)	1996-02-29
HU221434B (en)	2002-10-28
NO970831D0 (no)	1997-02-24
TW430663B (en)	2001-04-21
DK0777666T3 (da)	1999-09-27
NZ292683A (en)	1998-07-28
EP0777666B1 (de)	1999-03-03
JPH10504580A (ja)	1998-05-06
DE69508093T2 (de)	1999-07-15
NO970831L (no)	1997-04-18
US6329392B1 (en)	2001-12-11
HUT76644A (en)	1997-10-28
AU3492895A (en)	1996-03-14
GR3030253T3 (en)	1999-08-31
IL115040A (en)	2000-02-29
NO313237B1 (no)	2002-09-02
FI970771L (fi)	1997-02-24
MX9701305A (es)	1998-05-31
KR100362620B1 (ko)	2003-02-14
AU693936B2 (en)	1998-07-09
CA2198084C (en)	2000-03-28
DE69508093D1 (de)	1999-04-08
ES2132709T3 (es)	1999-08-16

Legal Events

Date	Code	Title	Description
1999-11-15	UEP	Publication of translation of european patent specification
2006-05-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69508093D1 (de)	1999-04-08	Substituierte piperidine für die behandlung von allergischen krankheiten
ATE250577T1 (de)	2003-10-15	Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
BG101806A (bg)	1998-04-30	Индолови производни като антагонисти на 5-нт рецептори
NO985977L (no)	1999-02-22	Spiro-piperidinderivater og deres anvendelse som terapeutiske midler
DE60038686D1 (de)	2008-06-05	Oheptan-derivate und ihre verwendung als integrin-rezeptor-antagonisten
ATE232858T1 (de)	2003-03-15	Substituierte 4-(1h-benzimidazol-2-yl- amino)piperidine zur behandlung allergischer erkrankungen
NO962855L (no)	1996-07-05	Nye piperidin-derivater med PAF-antagonist-aktivitet
MX9804991A (es)	1998-09-30	4-(1h-benzimidazol-2-il)(1,4) diazepanes sustituidos novedosos utiles para el tratamiento de enfermedades alergicas.
DE69717969D1 (de)	2003-01-30	Substituierte n-methyl-n-(4-(piperidin-1-yl)-2-arylbutyl)-benzamide zur behandlung von allergischen erkrankungen
ATE282417T1 (de)	2004-12-15	Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
CA2247105A1 (en)	1997-08-28	Novel substituted n-methyl-n-(4-(4-(1h-benzimidazol-2-yl-amino)piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic di seases
AR005895A1 (es)	1999-07-21	Derivados de n-metil-n-(4-(piperidin-1-il)-2-(aril)butil)benzamida sustituida, utiles como antagonistas de los receptores de histamina yantagonista de los receptores de taquiquininas y composicion farmaceutica que los contiene.